News Eisai settles Lenvima patent dispute with Torrent Pharma A settlement between Eisai and Torrent Pharma will keep a generic version of blockbuster cancer drug Lenvima off the US market until 2030.
News MSD still seeking deals 'with urgency' after Verona takeover MSD has only just completed its $10 billion takeover of Verona Pharma, but is still on the hunt for more bolt-on acquisitions.
News MSD, Eisai abandon combination trial in liver cancer MSD and Eisai's oncology partnership has had mixed fortunes this week, with a disappointment in liver cancer and encouraging data in kidney cancer.
News ESMO: Ivonescimab beats BeOne PD-1 in first-line lung cancer Akeso/Summit's PD-1xVEGF drug ivonescimab bests a PD-1 inhibitor as first-line therapy in Chinese NSCLC patients, but a bigger test is yet to come.
News MSD advances on a broad front with TL1A drug tulisokibart MSD's confidence in its anti-TL1A drug tulisokibart in inflammatory diseases is made apparent by a decision to start trials in three new indications.
News Verona shareholders back $10bn MSD takeover MSD has moved a step closer to completing its acquisition of Verona Pharma, after a vote in favour of the transaction by the UK firm's shareholders.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.